REGN Regeneron Pharmaceuticals Inc

Price (delayed)

$595.4

Market cap

$65.4B

P/E Ratio

7.94

Dividend/share

N/A

EPS

$74.98

Enterprise value

$64.76B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities , it ...

Highlights
The company's EPS has surged by 100% YoY
Regeneron Pharmaceuticals's net income has surged by 98% YoY
The gross margin has contracted by 2.5% YoY

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
109.85M
Market cap
$65.4B
Enterprise value
$64.76B
Valuations
Price to earnings (P/E)
7.94
Price to book (P/B)
3.25
Price to sales (P/S)
3.85
EV/EBIT
7.05
EV/EBITDA
6.83
EV/Sales
3.92
Earnings
Revenue
$16.51B
EBIT
$9.19B
EBITDA
$9.48B
Free cash flow
$7.94B
Per share
EPS
$74.98
Free cash flow per share
$74.31
Book value per share
$183.48
Revenue per share
$154.57
TBVPS
$246.71
Balance sheet
Total assets
$26.35B
Total liabilities
$6.43B
Debt
$2.7B
Equity
$19.91B
Working capital
$11.3B
Liquidity
Debt to equity
0.14
Current ratio
4.76
Quick ratio
3.95
Net debt/EBITDA
-0.07
Margins
EBITDA margin
57.4%
Gross margin
84.6%
Net margin
48.1%
Operating margin
55.1%
Efficiency
Return on assets
32.7%
Return on equity
44.7%
Return on invested capital
45%
Return on capital employed
39.4%
Return on sales
55.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
0.72%
1 week
-2.79%
1 month
-9.64%
1 year
3.62%
YTD
-5.72%
QTD
0.72%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$16.51B
Gross profit
$13.97B
Operating income
$9.09B
Net income
$7.93B
Gross margin
84.6%
Net margin
48.1%
The operating income has soared by 128% YoY
Regeneron Pharmaceuticals's net income has surged by 98% YoY
The revenue has soared by 79% YoY and by 2.7% QoQ
Regeneron Pharmaceuticals's gross profit has soared by 75% YoY and by 2.5% from the previous quarter

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
7.94
P/B
3.25
P/S
3.85
EV/EBIT
7.05
EV/EBITDA
6.83
EV/Sales
3.92
The company's EPS has surged by 100% YoY
REGN's price to earnings (P/E) is 58% lower than its 5-year quarterly average of 18.8 and 12% lower than its last 4 quarters average of 9.0
The equity has surged by 66% year-on-year and by 6% since the previous quarter
REGN's price to book (P/B) is 34% less than its 5-year quarterly average of 4.9 and 14% less than its last 4 quarters average of 3.8
The revenue has soared by 79% YoY and by 2.7% QoQ
The P/S is 41% lower than the 5-year quarterly average of 6.5 and 14% lower than the last 4 quarters average of 4.5

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has increased by 43% YoY but it has decreased by 10% QoQ
The return on assets has increased by 33% year-on-year but it has declined by 11% since the previous quarter
Regeneron Pharmaceuticals's return on equity has increased by 18% YoY but it has decreased by 13% QoQ
The company's return on sales rose by 15% YoY but it fell by 4.6% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
The quick ratio has soared by 65% YoY and by 33% from the previous quarter
The current ratio has soared by 53% YoY and by 34% QoQ
The debt is 86% less than the equity
The equity has surged by 66% year-on-year and by 6% since the previous quarter
REGN's debt to equity is down by 39% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.